Table 1.
Overall Consistency | Summary of Findings | ||||||
---|---|---|---|---|---|---|---|
| |||||||
Number of trials | Heterogeneity (quantitative) | Direction and statistical significance of results | Generalizability to resource poor settings | Heterogeneity of the intervention | Number of births | Statistical method | Pooled estimate (95% CI) |
Risk of preterm birth (<37 weeks): Overall quality of evidence grade= low | |||||||
16 | Q = 20.3, p = 0.16; I2 = 26% | 10 trials favored zinc; 2 of these statistically significant | 11 trials conducted in low or middle income countries | Daily zinc dose from 15 to 50 mg; augmentative and placebo-controlled trials | 7818 (963 preterm) | Mantel-Haenszel fixed-effects relative risk; Shore corrected 95% CI | 0.86 (0.75, 0.99) |
Risk of low birth weight (<2500 grams): Overall quality of evidence grade= very low | |||||||
11 | Q = 16.0, p = 0.10; I2 = 37% | 4 trials favored zinc; 2 of these statistically significant | 8 trials conducted in low or middle income countries | Daily zinc dose from 15 to 50 mg; augmentative and placebo-controlled trials | 5614 (937 low birth weight) | Mantel-Haenszel fixed-effects relative risk; Shore corrected 95% CI | 1.06 (0.91, 1.23) |
Risk of small for gestational age birth (as defined by individual authors): Overall quality of evidence grade= very low | |||||||
5 | Q = 9.8, p = 0.04; I2 = 59% | 2 trials favored zinc; 1 of these statistically significant | 4 trials conducted in low or middle income countries | Daily zinc dose from 25 to 45 mg; augmentative and placebo-controlled trials | 3441 (1155 SGA) | Mantel-Haenszel fixed-effects relative risk; Shore corrected 95% CI | 1.03 (0.91, 1.17) |
Mean difference in birth weight (grams): Overall quality of evidence grade= very low | |||||||
20 | Q = 77.4, p < 0.005; I2 = 75% | 11 trials favored zinc; 2 of these statistically significant | 13 trials conducted in low or middle income countries | Daily zinc dose from 5 to >50 mg; augmentative and placebo-controlled trials | 8138 | Inverse-variance weighted fixed-effects mean difference | 13 g (−9, 35) |
Mean difference in length at birth (centimeters): Overall quality of evidence grade= very low | |||||||
12 | Q = 16.0, p = 0.14; I2 = 31% | 6 trials favored zinc; 1 of these statistically significant | 9 trials conducted in low or middle income countries | Daily zinc dose from 5 to 50 mg; augmentative and placebo-controlled trials | 6285 | Inverse-variance weighted fixed-effects mean difference | −0.1 cm (−0.3, 0.0) |
Mean difference in gestational age at birth (weeks): Overall quality of evidence grade= very low | |||||||
12 | Q = 12.0, p = 0.37; I2 = 8% | 7 trials favored zinc; 1 of these statistically significant | 11 trials conducted in low or middle income countries | Daily zinc dose from 5 to >50 mg; augmentative and placebo-controlled trials | 5273 | Inverse-variance weighted fixed-effects mean difference | 0.1 cm (−0.1, 0.2) |
Mean difference in head circumference at birth (centimeters): Overall quality of evidence grade= very low | |||||||
11 | Q = 21.0, p = 0.02; I2 = 52% | 4 trials favored zinc; 2 of these statistically significant | 9 trials conducted in low or middle income countries | Daily zinc dose from 5 to 50 mg; augmentative and placebo-controlled trials | 5065 | Inverse-variance weighted fixed-effects mean difference | 0.0 cm (−0.1, 0.1) |
Table format adapted from Walker, Fischer-Walker, Bryce et al., International Journal of Epidemiology, 2010;39:i21–i31 and Cochrane Review Manager “Data and Analysis” pre-formatted table.
95% CI = Ninety-five percent confidence interval
mg = milligrams
g = grams
cm = centimeters
SGA = Small for gestational age
Q = Cochrane’s heterogeneity statistic
I2 = 100% × (Q − degrees of freedom)/Q
Quantitative measures of heterogeneity: large Q, small p, large I2 all indicate increased heterogeneity
All included results were derived from randomized controlled trials.
For binary outcomes, sRR < 1 favors zinc intervention (unfavorable outcome less likely).
For continuous outcomes, sMD > 0 favors zinc intervention (larger, more developed infants).
Number of births and number of events were estimated for one trial.
All summary estimates were calculated by fixed effects meta-analysis. Random effects estimates are provided in the text when appropriate.